6533b7cefe1ef96bd1257853
RESEARCH PRODUCT
Statins and metabolic syndrome
Maurizio AvernaAlessia Lo Verdesubject
medicine.medical_specialtyVery low-density lipoproteinbusiness.industryHypertriglyceridemianutritional and metabolic diseasesGeneral MedicineDiseasemedicine.diseaseEndocrinologyDiabetes mellitusInternal medicinemedicineCardiologylipids (amino acids peptides and proteins)RosuvastatinTherapeutic Lifestyle ChangesMetabolic syndromeRisk factorbusinessmedicine.drugdescription
Abstract Metabolic syndrome (MS) is a multifactorial condition that represents a risk factor for the development of diabetes mellitus (DMII) and cardiovascular disease (CVD). Statins may play a role on some modifiable clinical features of MS; in fact, whereas therapeutic lifestyle changes are mandatory for MS with a 10-year coronary heart disease (CHD) risk 20% and to correct the other associated lipid and non-lipid abnormalities. In fact, they have a VLDL lowering action in hypertriglyceridemia, they reduce the amount of small and dense LDL, they increase the HDL-C, they reduce the atherogenic lipoproteins, and they decrease the inflammatory marker levels.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-08-01 | International Congress Series |